Investigation of pharmacokinetics of roflumilast and roflumilast N-oxide after single morning or evening oral administration of 500 μg roflumilast in healthy subjects - an open, randomized, two-period crossover study

Study identifier:BY217/CP-043

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected]

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual enrollment

16

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jul 2001
Primary Completion Date: -
Study Completion Date: 01 Aug 2001

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Sponsors

Takeda

Collaborators

-

Inclusion and exclusion criteria